Geode Capital Management
ARTV icon

Geode Capital Management’s Artiva Biotherapeutics ARTV Stock Holding History

Geode Capital Management’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.79M Buy
532,389
+178,544
+50% +$1.8M ﹤0.01% 2978
2026
Q2 		$3.43M Buy
353,845
+252,150
+248% +$2.3M ﹤0.01% 3060
2026
Q1 		$655K Buy
101,695
+578
+0.6% +$2.86K ﹤0.01% 3492
2025
Q4 		$434K Sell
101,117
-9,779
-9% -$36.9K ﹤0.01% 3637
2025
Q3 		$319K Sell
110,896
-48,145
-30% -$129K ﹤0.01% 3773
2025
Q2 		$240K Sell
159,041
-251,416
-61% -$528K ﹤0.01% 3813
2025
Q1 		$1.23M Buy
410,457
+94,699
+30% +$511K ﹤0.01% 3231
2024
Q4 		$3.18M Buy
315,758
+6,828
+2% +$82K ﹤0.01% 2959
2024
Q3 		$4.77M Buy
+308,930
New +$3.58M ﹤0.01% 2781

Other funds holding ARTV

Revelation Capital Management
Revelation Capital Management Sausalito, California $8.01M AUM 49.3% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Y-Intercept (HK)
Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return
Bailard
Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Geode Capital Management's ARTV Position: Q3 2026 in Review

Geode Capital Management increased its Artiva Biotherapeutics (ARTV) stake by 50% in Q3 2026, buying an estimated $1.8M and bringing the position to 532,389 shares worth $3.79M. The position accounts for ﹤0.01% of the portfolio, ranked #2978.

Geode Capital Management first reported a position in ARTV in Q3 2024 and has held it in 9 quarters since. The position peaked at $4.77M in Q3 2024. 27 funds tracked by Wall St. Rank hold ARTV as of Q3 2026.

  • Geode Capital Management held 532,389 shares of Artiva Biotherapeutics worth $3.79M as of Q3 2026.
  • Geode Capital Management bought 178,544 Artiva Biotherapeutics shares in Q3 2026, an estimated $1.8M.
  • Artiva Biotherapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q3 2026, its #2978 holding.
  • Geode Capital Management first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 9 quarters since.
  • Geode Capital Management's Artiva Biotherapeutics position peaked at $4.77M in Q3 2024.
  • 27 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q3 2026.

Based on Geode Capital Management's 13F filing for Q3 2026, filed 6 Nov 2026.